Screener
Ginkgo Bioworks DNA Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
FAQ
- What is Ginkgo Bioworks's equity method investments?
- Ginkgo Bioworks (DNA) reported equity method investments of $13.31M in Q2 2026.
- What is the long-term trend for Ginkgo Bioworks's equity method investments?
- Over 3 years (2020 to 2023), Ginkgo Bioworks's equity method investments has grown at a -100.0% compound annual growth rate (CAGR), from $28.92M to $0.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Ginkgo Bioworks's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude